Fusion Peptides Inhibit NSF to Block Exocytosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to adequately regulate exocytosis of Weibel-Palade bodies, leading to severe pathological conditions such as inflammatory and thrombotic disorders, including unstable angina, myocardial infarction, and stroke, with a lack of effective means to treat or prevent these disorders.
Innovation Solution
Development of novel fusion peptides that inhibit N-ethylmaleimide Sensitive Factor (NSF) activity, specifically designed to cross cell membranes and block exocytosis, including those of Weibel-Palade bodies, thereby promoting anticoagulation, treating thrombosis, and reducing myocardial infarction severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to regulate exocytosis, then existing therapeutic approaches can be maintained, but effective treatment of thrombotic and inflammatory disorders cannot be achieved
Solution Approach 1:
The fusion peptide is divided into two functional domains: an N-terminal membrane translocation domain (amino acids 1-30) that enables cell penetration, and a C-terminal NSF inhibition domain (amino acids 31-60) that blocks exocytosis. This segmentation allows the peptide to sequentially achieve intracellular delivery and therapeutic effect, resolving the contradiction between maintaining conventional approaches and achieving effective thrombosis treatment.
Solution Approach 2:
The fusion peptide acts as an intermediary molecule that bridges the extracellular therapeutic agent and the intracellular NSF target. By incorporating a membrane-translocating domain, the peptide mediates the delivery of the NSF-inhibiting sequence across the cell membrane, enabling effective regulation of exocytosis in Weibel-Palade bodies and treatment of thrombotic disorders.
2Reliability
If membrane-impermeable NSF inhibitors are used, then NSF activity can be inhibited, but the inhibitors cannot cross cell membranes to reach intracellular targets
Solution Approach 1:
The invention merges two previously separate functions into a single fusion peptide: membrane translocation capability (from the N-terminal domain) and NSF inhibition activity (from the C-terminal domain). This combination allows the peptide to both cross the cell membrane and inhibit NSF, resolving the contradiction between inhibition capability and membrane permeability.
Solution Approach 2:
The fusion peptide functions as a composite molecular structure combining a hydrophobic membrane-translocating segment with a hydrophilic NSF-inhibiting segment. This composite design enables the molecule to interact with both the lipid bilayer membrane and the intracellular NSF protein, achieving both membrane penetration and reliable NSF inhibition.
3Stability of the object's composition
If exocytosis of Weibel-Palade bodies is not regulated, then normal cellular processes continue, but severe pathological conditions such as thrombosis and myocardial infarction occur
Solution Approach 1:
The fusion peptide applies preliminary anti-action by preventing pathological exocytosis before thrombotic events occur. By inhibiting NSF and blocking the release of pro-thrombotic contents from Weibel-Palade bodies, the peptide prevents the formation of thrombi and reduces the risk of myocardial infarction and stroke, while allowing normal regulated exocytosis to continue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion peptides effectively inhibit exocytosis, acting as anticoagulants, treating thrombosis, and decreasing the severity of myocardial infarction by targeting NSF activity, providing a therapeutic approach to manage related disorders.
Implementation Method 1
a first sequence which promotes translocation of the fusion peptide across a membrane
Implementation Method 2
a second sequence that inhibits N-ethylmaleimide sensitive factor (NSF) activity... the activity that is inhibited may be the disassembly activity of NSF
Data Source
AI summary
Methods and compositions for blocking exocytosis by inhibition of proteins that regulate exocytosis, such as N-ethylmaleimide Sensitive Factor (NSF), are provided. The compositions include multidomain fusion peptides containing a domain that causes the fusion peptide to cross the cellular membrane (e.g. a domain from the TAT protein of HIV) and a domain that inhibits NSF (e.g. a domain of NSF). Administration of the fusion peptide promotes anticoagulation, attenuates thrombosis, and decreases heart attack severity.